News & Updates

For manufacturers evaluating the future of their partnership strategy, this whitepaper offers a perspective on how connected operating  models help organizations anticipate change, adapt faster and create greater value across the product lifecycle. 

Despite unprecedented access to data and AI, many life sciences organizations still struggle to make confident commercial decisions. This whitepaper explores why decision readiness is the missing link and outlines practical strategies for breaking down data silos, aligning teams, and building a stronger foundation for growth.

Must Read: Experts in cell line development offer new insights into using transposase-mediated semi-targeted integrations and AI to identify robust and stable pools that can help you to meet IND and GMP milestones fast and effectively.  

Clinical feasibility is evolving. Instead of validating assumptions after a protocol is written, leading teams are embedding feasibility earlier—using real-world data and AI to iteratively pressure-test eligibility criteria, optimize study design, and build more recruitable protocols. In this session, TriNetX and Parexel share a modern feasibility workflow designed for clinical operations teams, including non-medical users empowered through natural language and AI translation. You’ll see how protocol criteria can be translated into executable queries, how “what-if” iteration improves protocol quality, and how feasibility insights can inform site and country strategies—faster and with more confidence.

As legacy PLM systems reach a critical transition point and vendor-driven changes force organizations to reevaluate their current platforms, medical device companies are facing a broader question: does their product development technology foundation support the speed, visibility, and control required today?

This session explores how medtech organizations are rethinking PLM as more than a standalone system, using it as a single source of truth that connects R&D, quality, and manufacturing. We'll examine how leading teams are streamlining the path from design and regulatory approval to production while leveraging simulation and AI to accelerate development and improve decision-making.

Attendees will learn:

• Why PLM disruption is driving a broader reassessment of product development technology foundations
• How PLM supports the transition from design and regulatory approval to controlled manufacturing  
• What it takes to establish a single source of truth across R&D, quality, and operations
• How simulation and AI can reduce iteration cycles and accelerate innovation

Relevance, authority, and trust still determine which pharma brands get found, whether search happens on Google or in the AI tools HCPs and patients are increasingly using first.

What has changed is not the strategy, but how those signals are built, delivered, and interpreted across traditional and AI-driven search environments. Content slowed by MLR cycles, fragmented workflows, and inconsistent governance cannot meet the speed and structure required for both traditional and AI-driven search. This session shows how pharma marketing teams can close the content execution gap to improve visibility, scale content delivery, and strengthen search performance across channels.

Attendees will learn how to:

• Improve content speed and reduce latency from creation to live
• Strengthen governance and medical review consistency
• Ensure content supports relevance, authority, and trust signals
• Increase visibility across both traditional and AI-driven search
• Identify where execution gaps are impacting HCP and patient reach

GLP-1 therapies have quickly changed the obesity and cardiometabolic care landscape but the impact is no longer limited to pharma pipelines. As these therapies expand across obesity, diabetes, cardiovascular risk, sleep apnea, liver disease, kidney disease, and long-term chronic care, the second-order effects are showing up across devices, diagnostics, manufacturing, supply chain, and patient support.

For strategy and corporate development leaders, the key question is how to read the market early. Which categories gain momentum, which face disruption, and where should companies reposition portfolio, capital, and partnerships before the shift becomes obvious?

This panel will explore how the obesity treatment wave is influencing drug delivery platforms, autoinjectors, oral formulations, patient monitoring, diagnostic testing, CDMO capacity, fill-finish infrastructure, packaging, and commercial strategy across the healthcare ecosystem.

What attendees will learn

• How GLP-1 growth is affecting demand for pens, autoinjectors, connected devices, adherence tools, and patient support models.
• Where diagnostics and monitoring may play a larger role in metabolic, liver, kidney, cardiovascular, and sleep-related care.
• How oral GLP-1s and next-generation formulations could change device and manufacturing needs.
• Why manufacturing capacity, fill-finish, packaging, and supply chain strategy are becoming key competitive factors.
• Where medtech, diagnostics, life science tools, and CDMO companies may find new growth, partnership, or market-entry opportunities.
• How leading companies are pressure-testing portfolio strategy against a fast-moving demand shift.